Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, explains the benefits of dual-targeting triplebodies.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.